of outcomes, including increased rates for birth defects such as neural tube defects and an increased risk of obstetric complications. Theoretical concerns about a relative folate deficiency have prompted some experts to suggest that women planning pregnancy while taking olanzapine should take 5 mg folate rather than the usual 0.5 mg to try and reduce the risk of neurodevelopmental disabilities. 6
Lactation
Limited information shows that maternal doses of olanzapine up to 20 mg/day produce low levels in milk and undetectable levels in breastfed infants. Generally, short-term adverse effects have not occurred, and sedation has not been reported. Limited long-term follow-up of infants exposed to olanzapine has been reassuring, particularly with monotherapy.
Conclusion
The potentially harmful effects of taking an antipsychotic drug in pregnancy have to be balanced against the harm of untreated 
New drugs
Some of the views expressed in the following notes on newly approved products should be regarded as tentative, as there may have been little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. As a result of fuller experience, initial comments may need to be modified. The Committee is prepared to do this. Before new drugs are prescribed, the Committee believes it is important that full information is obtained either from the manufacturer's approved product information, a drug information centre or some other appropriate source. 
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Abatacept should be given as a 30-minute intravenous infusion. The dose is dependent on the patient's body weight.
The infusion should be repeated at two and four weeks and then every four weeks after that. Following multiple 10 mg/kg intravenous infusions of abatacept, the serum concentration reaches a steady state after 60 days. The mean half-life is approximately 13 days in patients with rheumatoid arthritis, and clearance increases with body weight.
When given as a monotherapy to patients with severe active rheumatoid arthritis, more patients responded to abatacept (10 mg/kg) than to placebo. After 85 days, a 20% clinical improvement (based on the criteria of the American College of Rheumatology) was observed in 53% of patients on abatacept compared with 31% on placebo. 1 This study was primarily a dose-finding trial and so there were only 32 patients in the abatacept 10 mg/kg group. Abatacept appears to be efficacious when given in combination with other DMARDs. 2, 3, 4, 5, 6 In a trial of patients with active disease despite methotrexate, 652 patients were randomised to also receive abatacept or placebo. After a year, 73% of patients given abatacept had a 20% clinical improvement compared to only 40% of those given placebo. There was slower radiological progression of joint damage in the abatacept group. 4 In another trial patients who had not responded to anti-TNF therapy received either abatacept or placebo with another DMARD. More patients in the abatacept group than in the control group had a 20% improvement (50% vs 20% of patients after six months). However, reduced progression of joint damage was not established in these patients. 5 Infusion-related reactions, such as dizziness and headache, are common with abatacept. In a one-year safety trial of 1441 patients, serious infections were more frequent with abatacept than with placebo (2.9% vs 1.9%). Pneumonia was the most common type of serious infection. In patients receiving other biological drugs as well as abatacept, the rate of serious infections increased to 5.8%. Overall, the incidence of neoplasms was similar with abatacept compared to placebo (3.5%). However, this rate increased to 6.8% in patients who were also taking other biological drugs. In patients with chronic obstructive pulmonary disease, there were more adverse events with abatacept than with placebo. 7 As abatacept inhibits T cell activation, it may affect a patient's Exenatide has also been studied in patients whose diabetes has not been controlled by a thiazolidinedione with or without metformin. A group of 121 patients injected exenatide and 112 injected a placebo twice daily. After 16 weeks the HbA1c had decreased by 0.89% with exenatide 10 microgram and increased by 0.09% in the placebo group. 5 After the placebo-controlled trials, 668 patients who had taken exenatide continued using it in open-label extension studies. A total of 314 patients completed a further 52 weeks of treatment.
The reduction in HbA1c seen at the end of the placebocontrolled studies was maintained. 6 In the medium-term placebo-controlled studies, more patients dropped out of the exenatide groups because of adverse effects. 2, 3, 4, 5 In the trial adding exenatide to a thiazolidinedione, 16% of the patients withdrew because of adverse effects compared with only 2% of the patients who added a placebo. 5 A common problem with exenatide is nausea. It affects more than 40% of patients some of whom will vomit. Diarrhoea and dyspepsia are also more frequent than with placebo. There is an increased frequency of hypoglycaemia when exenatide is added to regimens containing a sulfonylurea. The dose of sulfonylurea may need to be reduced.
The exenatide molecule is not identical to human GLP-1.
Some patients will develop antibodies against exenatide.
Hypersensitivity reactions may occur and it is possible that high antibody titres could reduce the efficacy of exenatide.
During the 30-week trials, patients randomised to take exenatide lost 1-3 kg in weight. 2, 3, 4 In Europe there is a risk management plan to monitor for safety concerns such as pancreatitis and anti-exenatide antibodies.
Long-term outcomes with exenatide are currently unknown.
As it is relatively expensive, the use of exenatide may be limited to obese patients with insulin resistance, but this will require further study. At present, the Australian approval is for adjunctive therapy in patients who are not achieving adequate glycaemic control with metformin, a sulfonylurea, or both. In the phase II and III trials, genetic evidence of viral resistance was found following viral breakthrough in some patients. 3 In in vitro studies, some viral strains that showed resistance to other nucleotide/nucleoside analogues, such as lamivudine or adefovir, also had reduced susceptibility to telbivudine.
The safety profiles of telbivudine and lamivudine were comparable in the phase III trial, with muscle-related symptoms being the most common treatment-emergent clinical adverse events, occurring in 2% of all patients. Creatine kinase elevations occurred in 9% of telbuvidine-treated patients and 3% of lamivudine-treated patients.
Telbivudine comes with a warning about the risk of myopathy.
Patients taking telbivudine should therefore be advised to report any unexplained muscle aches, pain, tenderness or weakness.
Treatment should be stopped if myopathy is diagnosed.
Health professionals should also be aware that discontinuing telbivudine treatment may lead to severe acute exacerbations of hepatitis B infection. Hepatic function should be monitored for a minimum of several months once therapy has been stopped.
When monitoring hepatic function in patients taking telbivudine, check for flares in alanine transferase.
